Matthew Gall I Teos Therapeutics, Inc. (ITOS) insider trading activity

ITOS Quotes by TradingView

Matthew Gall is Chief Financial Officer of iTeos Therapeutics, Inc.. Currently has a direct ownership of 60,429 shares of ITOS, which is worth approximately $872,594. The most recent transaction as insider was on Dec 05, 2023, when has been sold 41,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 60.4K
0% 3M change
318.8% 12M change
Total Value Held $872,594

Matthew Gall Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 05 2023
BUY
Grant, award, or other acquisition
-
41,000 Added 40.42%
60,429 Common Stock
Oct 12 2023
BUY
Open market or private purchase
$41,849 $8.37 p/Share
5,000 Added 20.47%
19,429 Common Stock
Dec 27 2021
SELL
Open market or private sale
$232,250 $46.45 p/Share
5,000 Reduced 25.73%
14,429 Common Stock
Oct 11 2021
BUY
Exercise of conversion of derivative security
$88,883 $6.16 p/Share
14,429 Added 42.62%
19,429 Common Stock
Jun 16 2021
BUY
Open market or private purchase
$130,450 $26.09 p/Share
5,000 Added 50.0%
5,000 Common Stock
MG

Matthew Gall

Chief Financial Officer
Watertown, MA

Track Institutional and Insider Activities on ITOS

Follow iTeos Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ITOS shares.

Notify only if

Insider Trading

Get notified when an I Teos Therapeutics, Inc. insider buys or sells ITOS shares.

Notify only if

News

Receive news related to iTeos Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on ITOS